治疗房颤的新型药物屈奈达隆  

Dronedarone:a novel agent for treatment of atrial fibrillation

作　　者：李冬婷[1] 杨倩[1] 郭小可[1] 尤启冬[1] 

机构地区：[1]中国药科大学药学院药化教研室,南京210009

出　　处：《中国新药杂志》2011年第6期481-486,513,共7页Chinese Journal of New Drugs

基　　金：国家科技部"863"计划项目(2007AA02Z307)

摘　　要：房颤是最常见的心律失常病症,其发病率随着年龄的增长而提高。胺碘酮(Amiodarone)是治疗房颤的最有效药物之一,但因其严重心外不良反应,而使其应用大大受限。法国Sanofi-Aventis公司历经20多年研发了胺碘酮类似物屈奈达隆(dronedarone),并于2009年7月1日获美国FDA批准上市。文中对屈奈达隆的化学合成、药理学、药动学、临床试验研究进展做一综述。Atrial fibrillation is the most common type of cardiac arrhythmias,and its prevalence increases with age.Amiodarone is the most effective drug for treatment of atrial fibrillation;however,the usage of this drug was extensively limited due to its severe extra-cardiac side-effects.Dronedarone,the analogue of amiodarone,has been developed for over two decades by Sanofi-Aventis,a French company,and approved by the American Food and Drug Administration（FDA） on 1st July,2009.The chemical synthesis,pharmacology,pharmacokinetics,and clinical trials of dronedarone were reviewed in this paper.

关 键 词：心律失常 房颤 屈奈达隆 化学合成 临床试验 

分 类 号：R972.2[医药卫生—药品]